Medical technology company Inogen Inc (Nasdaq: INGN) announced on Monday that it has received FDA 510(k) clearance for the SIMEOX 200 Airway Clearance Device, enabling its introduction to the US market.
This next-generation device builds on the original Simeox, currently available internationally, to enhance bronchial drainage for patients with chronic respiratory diseases like Bronchiectasis, COPD, Cystic Fibrosis and Primary Ciliary Dyskinesia.
SIMEOX 200 uses high-frequency oscillatory vibrations and intermittent negative pressure during exhalation to mobilize bronchial secretions effectively, offering an innovative alternative to traditional airway clearance therapies. Designed for use in healthcare settings or at home, it is aimed at patients capable of independently generating a cough.
Inogen plans a limited US launch of the device in 2025, targeting specific sites. As a global leader in respiratory technology, Inogen continues to expand its portfolio of innovative homecare solutions, supporting patients and healthcare providers with advanced respiratory therapies.
Hikma announces Health Canada approval of KLOXXADO Nasal Spray for opioid overdose treatment
Johnson & Johnson reports breakthrough overall survival data for EGFR-mutated lung cancer treatment
Altesa BioSciences granted US regulatory approval for vapendavir clinical trials
Black Diamond Therapeutics and Servier agree global licensing deal for BDTX-4933
AstraZeneca secures EU approval for Imfinzi in limited-stage small cell lung cancer
Akeso's Penpulimab receives Chinese regulatory approval
Korro Bio receives FDA orphan drug designation for KRRO-110
Health Canada approves Johnson & Johnson therapy for advanced EGFR-mutated lung cancer
Polarean expands Xenon MRI imaging for pharma-sponsored research
Celltrion's OMLYCLO receives US FDA approval
Health Canada approves ALK's ACARIZAX for young children with dust mite allergy
Plus Therapeutics secures FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda
CStone Pharmaceuticals reports first patient dosed in CS2009 Phase I trial
AstraZeneca's Imfinzi recommended for EU approval in resectable NSCLC treatment